OS Therapies Incorporated - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
OSTX NYSE American 2834 ostherapies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OS Therapies Incorporated

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Oct 22nd, 2025 7:15 am
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Oct 17th, 2025 7:15 am
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma - Oct 10th, 2025 4:00 am
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting - Oct 9th, 2025 5:40 am
OS Therapies to Participate in Fall 2025 Conferences and Events - Oct 7th, 2025 9:50 am
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update - Sep 30th, 2025 5:40 am
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT - Sep 19th, 2025 5:40 am
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit - Sep 12th, 2025 5:40 am
Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX) - Sep 8th, 2025 3:13 pm
OS Therapies to Participate in Upcoming Investor Conferences in September 2025 - Sep 3rd, 2025 5:40 am
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting - Sep 2nd, 2025 5:40 am
OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing - Sep 2nd, 2025 4:00 am
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025 - Aug 27th, 2025 2:01 pm
OS Therapies Terminates Equity Line of Credit - Aug 25th, 2025 7:51 pm
Wall Street Set to Open Higher Friday as Investors Await Powell's Speech at Jackson Hole - Aug 22nd, 2025 6:57 am
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update - Aug 19th, 2025 4:00 am
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025 - Aug 14th, 2025 3:44 pm
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Aug 7th, 2025 7:00 am
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Aug 7th, 2025 4:00 am
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer - Jul 14th, 2025 5:40 am